Belfast-based contract research organisation Fusion Antibodies plc (AIM: FAB) reported on Monday that it has entered into an intellectual property transfer agreement with Finn Therapeutics Ltd, granting the client ownership of certain background IP related to a novel rabbit antibody.

The agreement delivers a one-off payment of GBP250,000 to Fusion, covering the IP and associated rights extending to humanised antibody sequences. The full value of the transaction will be recognised in the company's financial year ending 31 March 2026.

Finn Therapeutics has opted to acquire the IP to support its fundraising activities, with Fusion agreeing to tailored payment terms to facilitate this process. The client has an established relationship with Fusion, having already commissioned multiple projects, and has indicated its intention to continue collaboration as development of the humanised antibody progresses.

Fusion Antibodies provides pre-clinical antibody discovery, engineering and supply services to pharmaceutical and diagnostic companies. The company said the agreement reflects its strategy to leverage its scientific capabilities and intellectual property to support client development programmes while generating revenue through flexible commercial arrangements.